B. Seoane

发表

The Effect of Aclidinium on Symptoms Including Cough in Chronic Obstructive Pulmonary Disease: A Phase 4, Double-Blind, Placebo-controlled, Parallel-Group Study

S. Birring, J. Smith, J. Wedzicha, 2019, American journal of respiratory and critical care medicine.

Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study.

Deepak L. Bhatt, D. Schoenfeld, B. Scirica, 2018, Chronic obstructive pulmonary diseases.

Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator

I. Psallidas, C. Astbury, B. Seoane, 2020, Respiratory Research.

Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD

C. Astbury, J. Beier, G. de Miquel, 2016, BMC Pulmonary Medicine.

Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study

C. Vogelmeier, P. Śliwiński, A. Leselbaum, 2016, European Respiratory Journal.

Single Doses Of LAS100977, A Novel Long Acting ²2-agonist, Show High Activity And Long Duration In Healthy Subjects

W. Timmer, B. Seoane, E. Jiménez, 2010, ATS 2010.

Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study

J. Beier, R. Fuhr, B. Seoane, 2014 .

Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma.

J. Beier, R. Fuhr, G. de Miquel, 2014, Respiratory medicine.

Preference, satisfaction and critical errors with Genuair® and HandiHaler® in patients with COPD

E. G. Gil, A. Kroker, P. Valk, 2012 .

A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients.

H. Magnussen, C. Caracta, E. G. Gil, 2012, Pulmonary pharmacology & therapeutics.

Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre study

J. Haughney, H. Chrystyn, S. Pascual, 2015, npj Primary Care Respiratory Medicine.

Efficacy And Safety Of Single Inhaled Doses Of LAS100977, A Novel Long Acting ²2-agonist In Patients With Persistent Asthma

J. Beier, R. Fuhr, B. Seoane, 2010, ATS 2010.

A randomized placebo and active controlled trial of AZD8871 a novel dual acting bronchodilator in COPD patients

Dave Singh, C. Astbury, B. Seoane, 2017 .

A randomized placebo controlled trial of AZD8871 a novel dual acting bronchodilator in asthmatics

C. Astbury, B. Seoane, M. Albayaty, 2017 .

First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long‐acting Β2‐agonist

W. Timmer, G. de Miquel, B. Seoane, 2014, Journal of clinical pharmacology.

The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies

S. Birring, A. Morice, L. Mcgarvey, 2014 .

Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study

C. Astbury, J. Beier, B. Seoane, 2013 .

Preference, satisfaction and errors with two dry powder inhalers in patients with COPD

J. van der Palen, P. Van der valk, A. Kroker, 2013, Expert opinion on drug delivery.

Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD.

R. Casaburi, F. Maltais, B. Celli, 2011, Respiratory medicine.

Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials

S. Birring, J. Smith, A. Morice, 2016, BMJ Open Respiratory Research.

Aclidinium bromide improves symptoms and sleep quality in COPD: a pilot study

H. Magnussen, H. Watz, S. Andreas, 2017, European Respiratory Journal.

Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies

M. Malice, I. Psallidas, C. Astbury, 2020, Respiratory Research.

Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator

Dave Singh, I. Psallidas, C. Astbury, 2020, Respiratory Research.

The effect of aclidinium bromide 400 µg on sleep quality in COPD: A pilot study

H. Magnussen, H. Watz, S. Andreas, 2016 .

Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD

C. Vogelmeier, P. Śliwiński, A. Leselbaum, 2015 .

Efficacy, safety, and tolerability of once‐daily abediterol in patients with stable, persistent asthma: a Phase II, randomized, 7‐day, crossover study

J. Beier, R. Fuhr, G. de Miquel, 2017, Pharmacology research & perspectives.

A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study

Dave Singh, C. Astbury, A. Ribera, 2014, BMC Pulmonary Medicine.